Join to View Full Profile
1617 John F Kennedy BlvdSte 500Philadelphia, PA 19103
Phone+1 215-988-0080
Fax+1 215-988-1739
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 3 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. David Strayer, MD is an oncologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania and California.
Education & Training
University of California, Davis, School of MedicineClass of 1972
Certifications & Licensure
PA State Medical License 1980 - 2024
CA State Medical License 1973 - 2023
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 14 citationsEffect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.David R. Strayer, Diane Young, William M. Mitchell
Plos One. 2020-10-29 - 5 citationsProtection from pulmonary tissue damage associated with infection of cynomolgus macaques by highly pathogenic avian influenza virus (H5N1) by low dose natural human IF...David R. Strayer, William A. Carter, Bruce C. Stouch, Koert J. Stittelaar, Robert J. M. M. Thoolen
Antiviral Research. 2014-10-01 - 44 citationsIntranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humansEdgar T. Overton, Paul A. Goepfert, Pamela Cunningham, William A. Carter, Joseph C. Horvath
Vaccine. 2014-09-22
Press Mentions
AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue, Combination and Innovative Therapies for Pancreatic CancerMarch 29th, 2022- AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue: Combination and Innovative Therapies for Pancreatic CancerMarch 8th, 2022
- AIM ImmunoTech Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian CancerJanuary 24th, 2022
